Reirradiation and Erbitux in the HNSCC

• Patient with unresectable locoregional recurrence of squamous cell carcinoma in a previously irradiated area (at least 75% of the volume of recidivism must be in an area who have received at least 50 Gy)
• The entire tumor volume can be included in a radiation field without the total dose to the spinal cord more than 50 Gy (dose + dose earlier predicted)
• Patient with recurrent or second location in the oral cavity, oropharynx, larynx, hypopharynx, cervical lymph nodes or tissues, without distant metastases,
• Minimum 12 months after the end of radiotherapy previous
• WHO performance status: 0-1,
• Evaluable disease by RECIST V.1.1.,
• Age between 18 and 75 years
• The patient may have received prior chemotherapy for relapse for more than five weeks,
• The patient may have received cetuximab for the treatment of disease but not for the first relapse,
• Hematologic function: ANC ≥ 1500/mm3, Platelets ≥ 100000/mm3,
• Normal renal function: serum creatinine ≤ 120 µmol/l and/or creatinine clearance > 60 ml/min
• Normal liver function: bilirubin \<1.5 x ULN, alkaline phosphatase and transaminases \<2.5 x ULN,
• Normal cardiac function, assessed clinically. History of cardiovascular disease stabilized for over 12 months
• Cons-Lack of medical indications in the proposed treatment,
• The dosimetry of previous treatment should be available and the estimated dosimetry must be performed to check the constraints,
• All patients of childbearing age should receive effective contraception,
• Membership of a social security system (or be a beneficiary of such a plan) under the terms of the Act of August 9, 2004,
• Signed informed consent

Exclusion Criteria:

• Tumors of the nasal cavity and paranasal,
• Tumors of other histological type,
• Stage IV with distant metastases or multiple tumors,
• Time after previous radiotherapy \<12 months,
• Less than 75% of the volume of relapse who have previously received at least 50 Gy,
• Any medical condition or general-cons would indicate the completion of treatment. Systemic disease or uncontrolled infection,
• History of cancer other than head and neck cancer, cutaneous basal cell, carcinoma in situ of the cervix
• Any other concurrent anticancer therapy,
• Patient receiving another molecule experimental
• Pregnant, lactating or without contraception;
• Persons deprived of liberty under guardianship
• Inability to undergo medical test for geographical, social or psychological
• Nasopharyngeal Neoplasms
• Patients with active ischemic heart disease or previous myocardial infarction within the last 12 months
• Late toxicity dermal or subcutaneous related to previous irradiation of grade> 2 in the scale CTCAE V.4.